What is ACOG's market cap?

$182.93M, based on the Nov 4 close of $8.40.

Does Alpha Cognition pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ACOG is sold short?

352.5K shares, 1.8% of float, as of Oct 15, 2026.

What sector is ACOG in?

Healthcare, in the Biotechnology industry.

NASDAQ · ACOGHealthcareBiotechnology

Alpha Cognition Inc. Common Stock (ACOG)

$8.40+2.44%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$8.20▲ 43.86% in range

Nov 3, 2025Low $4.50 · High $9.75Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Alpha Cognition closed at $8.40 on Nov 4, up 2.44%, 13.8% below its 52-week closing high. Volume of 118.0K shares was 1.22× its 20-day average (close to normal).

Split-adjusted performance: -6.5% over one month, +31.7% over six months, +47.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $6.09M, up 267.6% from a year earlier, with a net margin of -144.3%.

Short interest was 352.5K shares at the Oct 15 settlement, up 9.0% from the prior report (1.8% of float, 3.8 days to cover).

Market cap$182.9M21.8M shares

Revenue · quarter$6.1M+267.6% YoY

Diluted EPS$-0.40—

P/E · TTM—P/S 12.0×

Net margin-144.3%Gross 93.6%

Dividend yieldNone

52-week range4.50 – 9.75−13.8% from high

Volume118.0K1.22× 20-day avg

Volatility · 60d44.8%Annualised

Short % of float1.8%3.8 days to cover

Net cash$41.4MCash $41.4M

Next earnings—Not scheduled

Split-adjusted performance

1W −8.4%1M −6.5%3M −3.1%6M +31.7%YTD +29.2%1Y +47.4%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum83

Revenue growth88

Net margin59

Value (low P/E)—

Size43

Industry medians: 6-month return −19.5%, revenue growth +8.8%, net margin −312.9%, P/E 22.2×.

Short interest

Details →

Shares short352.5K+9.0% vs prior

Days to cover3.8Settled Oct 15

% of float1.8%

Short vol. 10d38.3%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ACOGAlpha Cognition	$8.40	+2.44%	+31.7%	+267.6%	−144.3%	—	$182.9M
IVVDInvivyd	$0.6334	+8.93%	−56.6%	+21.2%	−310.8%	—	$186.7M	Compare
ARTVArtiva Biotherapeutics	$4.19	−0.36%	−66.2%	—	—	—	$204.6M	Compare
STROSutro Biopharma	$9.60	+0.95%	−74.5%	−84.6%	−391.6%	—	$159.2M	Compare
DTILPrecision BioSciences	$7.80	+11.91%	+3.7%	−100.0%	—	—	$215.3M	Compare
PALIPalisade Bio	$1.26	+2.03%	−37.3%	—	−2114.8%	—	$218.7M	Compare
PLXProtalix BioTherapeutics	$2.72	+4.21%	+34.7%	+27.1%	19.0%	11.6	$219.2M	Compare
IKTInhibikase Therapeutics	$1.60	+8.11%	−20.4%	—	—	—	$223.3M	Compare
PROKProKidney	$1.10	+2.34%	−44.1%	−32.1%	−18948.0%	—	$228.8M	Compare

News about Alpha Cognition

All news →

Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?Zacks Investment Research · Oct 23, 2026▼ Negative Alpha Cognition (ACOG) Q1 2026 Earnings TranscriptThe Motley Fool · May 14, 2026▲ Positive

Quick answers

What does Alpha Cognition do?: Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation.
What is ACOG's market cap?: $182.93M, based on the Nov 4 close of $8.40.
Does Alpha Cognition pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ACOG is sold short?: 352.5K shares, 1.8% of float, as of Oct 15, 2026.
What sector is ACOG in?: Healthcare, in the Biotechnology industry.

About Alpha Cognition

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

HQ: Grapevine, TX71 employeesListed Jun 9, 2021alphacognition.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology